Faruqi & Faruqi, LLP reminds investors of the August 31, 2026 deadline to seek lead plaintiff in a securities class action against Insulet Corporation. The lawsuit alleges Insulet made false and misleading statements by failing to disclose defective manufacturing controls that created a heightened risk of product safety violations or injury. The truth began to emerge on March 12, 2026, when Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, causing its stock to drop 6.88% to $219.84 per share. Then on May 26, 2026, Insulet disclosed another correction for Omnipod 5, Omnipod Dash, and Omnipod Eros Pods due to a manufacturing issue that could cause insulin under-delivery, sending shares down 5.07% to $146.01. Investors who purchased Insulet securities between February 21, 2025 and May 26, 2026 may be eligible to participate.
Insulet CorporationSecurities class action lawsuit alleges Insulet made false statements about defective manufacturing controls, leading to product corrections and stock drops.